摘要:
A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof is described.
摘要:
The use of a 5-HT1B/1D receptor agonist in the treatment or prevention of headache that results from administering an endothelin receptor antagonist; and the combination, comprising an endothelin receptor antagonist and a 5-HT1B/1D receptor agonist is described.
摘要:
The invention relates to the use of an anti-angiogenic agent in combination with an inhibitor of the Src family of non-receptor tyrosine kinases in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis, the Src kinase inhibitor being administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent.